Cancel anytime
Ideaya Biosciences Inc (IDYA)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/09/2024: IDYA (3-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: 53.86% | Upturn Advisory Performance 4 | Avg. Invested days: 51 |
Profits based on simulation | Stock Returns Performance 3 | Last Close 12/09/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: 53.86% | Avg. Invested days: 51 |
Upturn Star Rating | Stock Returns Performance 3 |
Profits based on simulation Last Close 12/09/2024 | Upturn Advisory Performance 4 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.40B USD |
Price to earnings Ratio - | 1Y Target Price 54.87 |
Dividends yield (FY) - | Basic EPS (TTM) -2.33 |
Volume (30-day avg) 954964 | Beta 0.86 |
52 Weeks Range 25.20 - 47.73 | Updated Date 12/10/2024 |
Company Size Mid-Cap Stock | Market Capitalization 2.40B USD | Price to earnings Ratio - | 1Y Target Price 54.87 |
Dividends yield (FY) - | Basic EPS (TTM) -2.33 | Volume (30-day avg) 954964 | Beta 0.86 |
52 Weeks Range 25.20 - 47.73 | Updated Date 12/10/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5730.6% |
Management Effectiveness
Return on Assets (TTM) -15.85% | Return on Equity (TTM) -21.1% |
Revenue by Products
Revenue by Products - Current and Previous Year
Valuation
Trailing PE - | Forward PE 4.65 |
Enterprise Value 1500706694 | Price to Sales(TTM) 611.11 |
Enterprise Value to Revenue 382.64 | Enterprise Value to EBITDA -7.8 |
Shares Outstanding 86431800 | Shares Floating 85536366 |
Percent Insiders 1.04 | Percent Institutions 111.21 |
Trailing PE - | Forward PE 4.65 | Enterprise Value 1500706694 | Price to Sales(TTM) 611.11 |
Enterprise Value to Revenue 382.64 | Enterprise Value to EBITDA -7.8 | Shares Outstanding 86431800 | Shares Floating 85536366 |
Percent Insiders 1.04 | Percent Institutions 111.21 |
Analyst Ratings
Rating 4.67 | Target Price 36.08 | Buy 3 |
Strong Buy 11 | Hold 1 | Sell - |
Strong Sell - |
Rating 4.67 | Target Price 36.08 | Buy 3 | Strong Buy 11 |
Hold 1 | Sell - | Strong Sell - |
AI Summarization
Ideaya Biosciences Inc. (IDYA): Comprehensive Overview
Company Profile
History and Background: Founded in 2015, Ideaya Biosciences is a clinical-stage biotechnology company focused on developing novel therapies for neurological and neurodevelopmental disorders. The company emerged from Pfizer's venture capital arm and has its headquarters in Morrisville, North Carolina.
Core Business Areas: Ideaya focuses on two main areas:
- Gene therapy: Leveraging adeno-associated virus (AAV) vectors to deliver therapeutic genes to specific regions of the brain.
- Small molecule therapies: Developing small molecules that modulate key pathways associated with neurological disorders.
Leadership and Corporate Structure:
- Yujiro Hata, MD, PhD: President and CEO, with extensive experience in drug development and commercialization.
- Michael Kishbauch, PhD: Chief Scientific Officer, leading the research and development efforts.
- Maria Collazo, MBA: Chief Financial Officer, responsible for financial strategy and operations.
Top Products and Market Share
Top Products:
- IDE163: A gene therapy for treating Fragile X syndrome in development.
- IDE399: A gene therapy for treating Rett syndrome in development.
- IDE019: A small molecule therapy for treating epilepsy in development.
Market Share: Ideaya currently has no marketed products. As a clinical-stage company, its market share is limited to its development pipeline. However, its potential target markets are significant:
- Fragile X syndrome: 400,000-600,000 individuals worldwide.
- Rett syndrome: 350,000 individuals worldwide.
- Epilepsy: 50 million individuals worldwide.
Competitive Landscape: Competitors in the gene therapy space for neurological disorders include AveXis, BioMarin, and Orchard Therapeutics. In the small molecule epilepsy space, competitors include UCB, Eisai, and GW Pharmaceuticals.
Total Addressable Market
The total addressable market for Ideaya's potential products is estimated to be over $10 billion globally, with significant growth potential as the understanding and treatment of neurological disorders evolve.
Financial Performance
Recent Financials: As of June 30, 2023, Ideaya reported:
- Revenue: $0 (pre-commercial stage)
- Net Income: $(44.2) million
- Cash and Cash Equivalents: $273.5 million
Financial Health: The company has a solid cash position to fund ongoing clinical trials. However, it is important to note that as a clinical-stage company, Ideaya is not yet profitable and relies on external funding to support its operations.
Dividends and Shareholder Returns
Dividend History: Ideaya does not currently pay dividends.
Shareholder Returns: Since its IPO in 2021, Ideaya's stock price has been volatile, reflecting the uncertainties associated with its clinical-stage pipeline.
Growth Trajectory
Historical Growth: Ideaya has demonstrated rapid growth in its early years, fueled by funding rounds and advancements in its development pipeline.
Future Growth: The company's future growth will depend on the success of its clinical trials and subsequent commercialization efforts. If successful, Ideaya has the potential to become a significant player in the neurology market.
Market Dynamics
Industry Trends: The market for neurological therapies is growing rapidly, driven by increasing prevalence of neurological disorders and advancements in technology.
Competitive Landscape: The market is becoming increasingly competitive, with several companies vying for market share. However, Ideaya's focus on gene therapy and rare neurological disorders provides it with a unique opportunity.
Competitors
Key Competitors:
- Gene Therapy: AveXis (AVXS), BioMarin (BMRN), Orchard Therapeutics (ORTX)
- Small Molecule Epilepsy: UCB (UCBJF), Eisai (OTCPK:ESALY), GW Pharmaceuticals (GWPH)
Competitive Advantages: Ideaya's differentiated gene therapy platform and focus on rare neurological disorders could provide it with a competitive advantage.
Competitive Disadvantages: The company's lack of marketed products and late-stage clinical assets compared to its competitors is a disadvantage.
Potential Challenges and Opportunities
Challenges:
- Clinical Trial Risks: The success of Ideaya's development pipeline is not guaranteed, and clinical trials can be expensive and time-consuming.
- Competition: The company faces intense competition in both the gene therapy and small molecule epilepsy markets.
- Regulatory Approval: Obtaining regulatory approval for new therapies can be challenging and lengthy.
Opportunities:
- Large Market Potential: The market for neurological therapies is vast and growing rapidly.
- Technological Advancements: New technologies in gene therapy and drug discovery could provide Ideaya with a competitive edge.
- Strategic Partnerships: Collaborations with other companies could accelerate Ideaya's development and commercialization efforts.
Recent Acquisitions
Ideaya has not made any acquisitions in the last three years.
AI-Based Fundamental Rating
Rating: 7/10
Justification: Ideaya has a promising pipeline of gene therapy and small molecule candidates targeting significant unmet medical needs. The company's strong leadership team and financial backing position it well for future growth. However, clinical trial risks and competition remain key challenges.
Sources:
- Ideaya Biosciences Investor Relations: https://investors.ideyabio.com/
- Crunchbase: https://www.crunchbase.com/organization/ideaya-biosciences
- BioSpace: https://www.biospace.com/
- ClinicalTrials.gov: https://clinicaltrials.gov/
Disclaimer:
This information is provided for informational purposes only and should not be considered financial advice. Please consult with a qualified financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ideaya Biosciences Inc
Exchange | NASDAQ | Headquaters | South San Francisco, CA, United States |
IPO Launch date | 2019-05-23 | President, CEO & Director | Mr. Yujiro S. Hata |
Sector | Healthcare | Website | https://www.ideayabio.com |
Industry | Biotechnology | Full time employees | 124 |
Headquaters | South San Francisco, CA, United States | ||
President, CEO & Director | Mr. Yujiro S. Hata | ||
Website | https://www.ideayabio.com | ||
Website | https://www.ideayabio.com | ||
Full time employees | 124 |
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.